Hariharasudan Natarajan
@beanbuddy.bsky.social
Kidney doc in training. Aspire to become a strong academician & clinician. I luv anime, traveling & exploring different cuisine.
Reposted by Hariharasudan Natarajan
Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC
Infographic by @nephroseeker.medsky.socia
Infographic by @nephroseeker.medsky.socia
September 3, 2025 at 1:52 AM
Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC
Infographic by @nephroseeker.medsky.socia
Infographic by @nephroseeker.medsky.socia
Reposted by Hariharasudan Natarajan
Agree
We do try it very cautiously for hypertension
And we do use it a bunch in PD for managing hypOkalemia pubmed.ncbi.nlm.nih.gov/29125879/
#NephJC
We do try it very cautiously for hypertension
And we do use it a bunch in PD for managing hypOkalemia pubmed.ncbi.nlm.nih.gov/29125879/
#NephJC
Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients - PubMed
Spironolactone is safe and effective in treating hypokalemia in PD patients. It is also an effective antihypertensive agent and merits further study in the PD population.
pubmed.ncbi.nlm.nih.gov
September 3, 2025 at 1:48 AM
Agree
We do try it very cautiously for hypertension
And we do use it a bunch in PD for managing hypOkalemia pubmed.ncbi.nlm.nih.gov/29125879/
#NephJC
We do try it very cautiously for hypertension
And we do use it a bunch in PD for managing hypOkalemia pubmed.ncbi.nlm.nih.gov/29125879/
#NephJC
Reposted by Hariharasudan Natarajan
T3b:
But… theoretical reasons do not matter anymore since in this well done, large trial with absolutely no benefit of spironolactone in ESRD. Coupled with the risk of serious hyperkalemia, spironolactone should no longer be used for CV protection in ESRD. #NephJC
But… theoretical reasons do not matter anymore since in this well done, large trial with absolutely no benefit of spironolactone in ESRD. Coupled with the risk of serious hyperkalemia, spironolactone should no longer be used for CV protection in ESRD. #NephJC
September 3, 2025 at 1:44 AM
T3b:
But… theoretical reasons do not matter anymore since in this well done, large trial with absolutely no benefit of spironolactone in ESRD. Coupled with the risk of serious hyperkalemia, spironolactone should no longer be used for CV protection in ESRD. #NephJC
But… theoretical reasons do not matter anymore since in this well done, large trial with absolutely no benefit of spironolactone in ESRD. Coupled with the risk of serious hyperkalemia, spironolactone should no longer be used for CV protection in ESRD. #NephJC
Reposted by Hariharasudan Natarajan
T0c:
💔 CV morbidity & mortality in ESRD is driven by:
🔹 Cardiac remodeling, ischemia and myocardial fibrosis
All fueled by chronic pressure–volume overload + inadequate salt/water excretion → relative hyperaldosteronism 🧂 #NephJC
www.imrpress.com/jou...
💔 CV morbidity & mortality in ESRD is driven by:
🔹 Cardiac remodeling, ischemia and myocardial fibrosis
All fueled by chronic pressure–volume overload + inadequate salt/water excretion → relative hyperaldosteronism 🧂 #NephJC
www.imrpress.com/jou...
September 3, 2025 at 1:09 AM
T0c:
💔 CV morbidity & mortality in ESRD is driven by:
🔹 Cardiac remodeling, ischemia and myocardial fibrosis
All fueled by chronic pressure–volume overload + inadequate salt/water excretion → relative hyperaldosteronism 🧂 #NephJC
www.imrpress.com/jou...
💔 CV morbidity & mortality in ESRD is driven by:
🔹 Cardiac remodeling, ischemia and myocardial fibrosis
All fueled by chronic pressure–volume overload + inadequate salt/water excretion → relative hyperaldosteronism 🧂 #NephJC
www.imrpress.com/jou...